NASDAQ:CMPS Compass Pathways (CMPS) Stock Price, News & Analysis $11.53 -0.47 (-3.92%) Closing price 04:00 PM EasternExtended Trading$11.61 +0.08 (+0.67%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Compass Pathways Stock (NASDAQ:CMPS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Compass Pathways alerts:Sign Up Key Stats Today's Range$11.53▼$12.0550-Day Range$11.47▼$15.1952-Week Range$4.88▼$15.87Volume1.96 million shsAverage Volume2.84 million shsMarket Capitalization$1.60 billionP/E RatioN/ADividend YieldN/APrice Target$23.36Consensus RatingModerate Buy Company Overview Compass Pathways plc is a biotechnology company developing psychedelic treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting. Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not achieve adequate relief from standard therapies. Its research has also explored the potential use of COMP360 in other serious mental health disorders. COMP360 is an investigational therapy and has not been approved for commercial use by regulatory authorities. Founded in 2016, Compass Pathways is headquartered in London and has conducted clinical development activities in the United States, the United Kingdom and other European countries. The company’s leadership includes Chief Executive Officer Kabir Nath, who joined Compass Pathways after holding senior positions in the biopharmaceutical industry.AI Generated. May Contain Errors. Read More Compass Pathways Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCMPS MarketRank™: Compass Pathways scored higher than 50% of companies evaluated by MarketBeat, and ranked 565th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCompass Pathways has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCompass Pathways has a consensus price target of $23.36, representing about 102.6% upside from its current price of $11.53.Amount of Analyst CoverageCompass Pathways has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Compass Pathways' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Pathways are expected to decrease in the coming year, from ($1.26) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Pathways is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Pathways is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Compass Pathways' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.66% of the float of Compass Pathways has been sold short.Short Interest Ratio / Days to CoverCompass Pathways has a short interest ratio ("days to cover") of 5.87.Change versus previous monthShort interest in Compass Pathways has recently increased by 11.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Pathways does not currently pay a dividend.Dividend GrowthCompass Pathways does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.14 News SentimentCompass Pathways has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Compass Pathways this week, compared to 5 articles on an average week.Search InterestOnly 18 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows9 people have added Compass Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compass Pathways insiders have not sold or bought any company stock.Percentage Held by Insiders2.82% of the stock of Compass Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of Compass Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Pathways' insider trading history. Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Pathways and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPS Stock News HeadlinesCompass Pathways Announces New Employee Inducement Grants under Nasdaq Listing Rule 5635(4)October 5, 2026 | marketscreener.comMCompass Pathways : Celebrates Opening of New U.S. Office in Jersey City, New JerseyOctober 5, 2026 | marketscreener.comMIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.October 12 at 1:00 AM | Banyan Hill Publishing (Ad)Compass Pathfinder Limited: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | finanznachrichten.deCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | businesswire.comCompass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Average Target Price of $23.36 According to BrokeragesOctober 1, 2026 | americanbankingnews.comCOMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III ProgressOctober 1, 2026 | finance.yahoo.comCOMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeptember 17, 2026 | seekingalpha.comSee More Headlines CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? Compass Pathways' stock was trading at $6.90 at the beginning of 2026. Since then, CMPS stock has increased by 67.1% and is now trading at $11.53. How were Compass Pathways' earnings last quarter? Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) announced its earnings results on Wednesday, August, 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $1.49. Read the conference call transcript. When did Compass Pathways IPO? Compass Pathways (CMPS) raised $112 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 7,500,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Compass Pathways' major shareholders? Compass Pathways' top institutional investors include Farther Finance Advisors LLC (0.02%). Insiders that own company stock include Life Sciences NV Atai, Ekaterina Malievskaia and George Jay Goldsmith. View institutional ownership trends. How do I buy shares of Compass Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Pathways investors own include Symbotic (SYM), Enovix (ENVX), Rambus (RMBS), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings8/05/2026Today10/12/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CMPS's financial health is in the Green zone, according to TradeSmith. CMPS has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CMPS CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees156Year Founded2016Price Target and Rating Average Price Target for Compass Pathways$23.36 High Price Target$65.00 Low Price Target$13.00 Potential Upside/Downside+102.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$287.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.63% Return on Assets-13.08% Debt Debt-to-Equity Ratio0.60 Current Ratio1.30 Quick Ratio1.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.55) per share Price / Book-20.96Miscellaneous Outstanding Shares138,480,000Free Float134,572,000Market Cap$1.60 billion OptionableOptionable Beta2.55 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CMPS) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMy biggest prediction yet?!James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years lat...Paradigm Press | SponsoredThe AI Stock to Keep an Eye on Before Election Day (See Why)In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he'...Prosperity Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Pathways With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPS Stock Alerts